Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations

Published 2020 View Full Article

Authors

Keywords

Journal

BMJ Open

Volume 10, Issue 10, Pages e039168

Publisher

BMJ

Online

2020-10-16

DOI

10.1136/bmjopen-2020-039168

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

BMJ Open

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Become a Peeref-certified reviewer